We caught up with Dr Arvin Haghighatfard to discuss why he chose CANTAB to investigate the effects of neuregulin 1 on executive dysfunction in autism spectrum disorder.
Cognitive dysfunction in Parkinson’s disease remains a significant, unmet therapeutic need for patients; as such it is vital that there is rigorous research into the topic. Here we will discuss six CANTAB tasks that can address this research gap.
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
Cognitive dysfunction is a leading cause of disability in multiple sclerosis (MS), yet practical restraints mean it often goes unassessed in routine clinical care. Promising new research, published in Frontiers in Neurology, suggests the Cambridge Neuropsychological Test Automated Battery (CANTAB) may offer a brief and sensitive technological solution.
Mood disorders affect 5-10% of the adult population in a given year. The most common mood disorders are major depressive disorder, dysthymia, and bipolar disorder. Here we explore the six CANTAB tests for objectively measuring cognitive function in depression.